ISRCTN14084351 https://doi.org/10.1186/ISRCTN14084351

Assessment of the effectiveness and safety of Bibrocathol 2% eye ointment (Bibrocathol-POS 2%) in the treatment of chronic blepharoconjunctivitis

Submission date
03/02/2021

Recruitment status
No longer recruiting

Registration date
08/03/2021

Overall study status
Completed

Last Edited
09/09/2022

Condition category
Eye Diseases

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol

Background and study aim
Blepharoconjunctivitis occurs when normal bacteria that live on the eyelid skin cause irritation and inflammation to the eyelids that spreads to the conjunctiva (the clear tissue covering the white part of the eye and the inside of the eyelids).
Bibrocathol is a well known antiseptic drug for the treatment of the signs and symptoms of chronic blepharoconjunctivitis, and is widely used in clinical practice. The aim of this study is to test the effectiveness and safety of Bibrocathol 2% eye ointment (Bibrocathol-POS 2%) in chronic blepharoconjunctivitis.

Who can participate?
Patients with chronic blepharoconjunctivitis may participate in this study if they do not yet require antibiotic treatment

What does the study involve?
The study includes four visits (screening, baseline, control assessment and final examination). The total duration of study for one patient is about 2-3 weeks. Eye examinations include measurement of visual acuity, intraocular pressure (the fluid pressure inside the eye), and slit-lamp biomicroscopy. A questionnaire is completed and physical examinations including blood pressure and weight measurement are performed at screening day. If applicable, a pregnancy test is carried out at screening. A patient diary is used to document the application of the investigational product by the patient.

What are the possible benefits and risks of participating?
The patient can benefit from bibrocathol and vehicle treatment or at least from the care and diagnostic supervision of the investigator. Eventually, it may be that there is no direct benefit from the participation in the study. However, participation in this study may possibly contribute to improved future treatment of other patients with the same or a comparable disease.

Where is the study run from?
URSAPHARM Arzneimittel GmbH (Germany)

When is the study starting and how long is it expected to run for?
November 2014 to October 2019

Who is funding the study?
URSAPHARM Arzneimittel GmbH (Germany)

Who is the main contact?
Dorothea Gross
d.gross@ursapharm.de

Contact information

Type(s)
Scientific

Contact name
Mrs Dorothea Groß

Contact details
Industriestrasse 35
Saarbrücken
Germany
66129
+49 (0)6805 9292 132
dorothea.gross@ursapharm.de

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
Nil known

Study information

Scientific Title
A multi-centre, randomized, double-masked, placebo-controlled, parallel-group, phase III study to assess efficacy and safety of Bibrocathol 2% eye ointment (Bibrocathol-POS 2%) in the treatment of chronic blepharoconjunctivitis

Study objectives

Assessment of a reduction in the signs and symptoms of chronic blepharoconjunctivitis.

Ethics approval required
Old ethics approval format

Ethics approval(s)
1. Approved 17/04/2017, Ethics Committee of Federal State Budgetary Educational Institution of Higher Education “Russian National Research Medical University n.a N.I. Pirogov” of the Ministry of Health of the Russian Federation (Ostrovityanova str. 1,117997, Moscow, Russian Federation; +7 (0)495 343 30 83; ek@rsmu.ru), ref: not available
2. Approved 10/04/2017, Ethics Committee of Federal State Budgetary Institution “Moscow Helmholtz Scientific Research Institute of Eye Diseases” of the Ministry of Healthcare of the Russian Federation (Sadovaya-Chernogryazskaya str. 14/19, 105062, Moscow, Russian Federation; +7 (0)495 623 41 61; info@igb.ru), ref: not available
3. Approved 17/05/2017, Ethics Committee of Federal State Budgetary Educational Institution of Higher Education “Saint Petersburg State Pediatric Medical University” of the Ministry of Healthcare of the Russian Federation (Litovskaya str. 2, 194100, Saint Petersburg, Russian Federation; +7 (0)812 295 9146; dogovor@gpma.ru), ref: not available
4. Approved 11/09/2017, Ethics Committee of Federal State Budgetary Educational Institution of Higher Education “Pavlov First Saint Petersburg State Medical University” of the Ministry of Healthcare of the Russian Federation (L’va Tolstogo str. 6/8, 197022, Saint Petersburg, Russian Federation; +7 (0)812 338 66-17; spbgmutrials@yandex.ru), ref: not available
5. Approved 26/05/2017, Local Ethics Committee of Regional Budgetary Healthcare Institution "Ivanovo Regional Clinical Hospital" (Luybimova str. 1, 153040, Ivanovo, Russia Federation; +7 (0) 4932 56 22 48; email: not available), ref: not available

Study design
Interventional multi-centre randomized double-masked placebo-controlled parallel-group trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Other

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied
Chronic blepharoconjunctivitis

Interventions

Patients are randomized with a 1:1 (verum: placebo) allocation ratio. A strip of the investigational product (about 5 mm) is administered in the conjunctival sac and on the lower and upper eyelid in the morning, at noon, and in the evening for 2 weeks.

Intervention Type
Drug

Phase
Phase III

Drug/device/biological/vaccine name(s)
Bibrocathol 2% eye ointment (Bibrocathol-POS 2%); 4,5,6,7-Tetrabromo-1,3,2-benzodioxabismol-2-ol

Primary outcome measure
Signs of chronic blepharoconjunctivitis, expressed as a sum score which comprises the severity of:
1. Lid oedema measured using slit-lamp examination at screening, day 1, day 7 and day 15
2. Lid erythema measured using slit-lamp examination at screening, day 1, day 7 and day 15
3. Debris measured using slit-lamp examination at screening, day 1, day 7 and day 15
4. Hyperemia measured using slit-lamp examination at screening, day 1, day 7 and day 15
5. Pouting of Meibomian glands assessed by the investigator at screening, day 1, day 7 and day 15

Secondary outcome measures
The individual parameters:
1. Lid oedema measured using slit-lamp examination at screening, day 1, day 7 and day 15
2. Lid erythema measured using slit-lamp examination at screening, day 1, day 7 and day 15
3. Debris measured using slit-lamp examination at screening, day 1, day 7 and day 15
4. Hyperemia measured using slit-lamp examination at screening, day 1, day 7 and day 15
5. Pouting of Meibomian glands measured by investigator assessment at screening, day 1, day 7 and day 15

Overall study start date
17/11/2014

Completion date
28/10/2019

Eligibility

Key inclusion criteria
1. Written informed consent
2. Ambulatory male and female patients ≥18 years of age
3. Diagnosis of chronic blepharoconjunctivitis
4. A summarised score of signs and symptoms (sum score of severity of lid oedema, lid erythema, debris, hyperemia and pouting of Meibomian glands and additionally the patient’s assessment of ocular discomfort) of ≥ 18 at baseline
5. Ability of the patient to cooperate (able to understand the provided information about the

clinical trial, willing to comply with the requirements of the study protocol)
6. Consent to use adequate contraception
7. Women using adequate contraception with a negative pregnancy test (for women with childbearing potential), or women who had menopause 2 years before the start of the study or earlier

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Sex
Both

Target number of participants
200 patients randomized (100 verum; 100 placebo)

Total final enrolment
200

Key exclusion criteria
Non-inclusion criteria:
Ocular conditions:
1. Chronic blepharoconjunctivitis requiring antibiotic treatment
2. Therapy-resistant chronic blepharoconjunctivitis
3. Acute ocular and/or follicle or lid infection or active ocular inflammation other than blepharoconjunctivitis
4. Irritations of the outer eye that are related to corneal damage (e. g. erosions, injuries, burns)
5. Abnormal eyelid anatomy (other than due to chronic blepharoconjunctivitis)
6. Ocular surgery within 90 days (trauma, intraocular surgery, refractive surgery, palpebral surgery (e.g. ectopium OP), etc)
7. Severe dry eye syndrome also due to systemic diseases
8. Allergic eye disease
9. Glaucoma
10. IOP ≥21 mmHg (non-contact tonometry)
11. Patients with only one eye

Systemic condition:
12. Known hypersensitivity to the investigational product or any of the ingredients from the composition of the investigational product (or of placebo)
13. Severe systemic disease (incl. rheumatoid arthritis, ankylosing spondylitis)
14. Subjects with a history of malignancy of any organ system, treated or untreated, within the past 5 years, whether or not evidence of local recurrence or metastases exists

Concomitant medication:
15. Oral or topical antibiotics 2 weeks prior to and during the trial
16. Any other ocular antiseptics during the trial

17. Topical ocular or systemic corticosteroids 2 weeks prior to and during the trial (except chronic use of inhalative corticosteroids if on stable dose 1 month prior to and during the trial)
18. Topical ocular and systemic NSAIDs 2 weeks prior to and during the trial (low-dose oral acetylsalicylic acid and occasional use of painkillers is allowed)
19. Local ocular use of antihistamines 1 month and prior to and during the trial
20. Ocular α-sympathomimetics 1 month and prior to and during the trial

Other:
21. Patients who anticipate changes in their ongoing regimen of concurrent systemic therapies that could affect trial parameters
22. Pregnant or breastfeeding women
23. Women with childbearing potential, not using a reliable and medically accepted method of contraception (no pregnancy test is required in women, being 2 years after menopause)
24. Any systemic or ocular medical or physical condition which, in the investigator’s opinion, would preclude the participant from adhering to the protocol or completing the trial per protocol
25. Patients participating in another clinical trial at the same time
26. Patients taking any investigational product during the last 28 days
27. Patients already once included in this trial

Exclusion criteria:
1. Recall of the informed consent by the patient
2. Necessity to discontinue study treatment /placebo due to the occurrence of adverse events and/or exacerbation of concurrent diseases which prevent further participation in the study
3. Applicability of adjunctive therapy which is not permitted within this Protocol
4. Other conditions or events which require, in the physician's opinion, withdrawal of the patient from the study. If such a decision is taken based on adverse events related to intake of test medications or comparative medications, the Study Sponsor or its representatives shall be informed immediately
5. Non-performance of the case monitoring of the parameters specified in the Study Protocol
6. Intake/use by the patient of medications prohibited within this study
7. The patient’s nonobservance of the procedures prescribed by the Protocol
8. Administrative reasons (discontinuation of the study by the Sponsor or regulatory authorities), and gross violations of the Protocol with a potential to impact the findings
9. Any changes in performing lid hygiene during the study
10. Wearing of contact lenses during the study

Date of first enrolment
15/01/2018

Date of final enrolment
15/02/2019

Locations

Countries of recruitment
Russian Federation

Study participating centre

Federal State Budgetary Educational Institution of Higher Education “Russian National Research Medical University n.a N.I. Pirogov” of the Ministry of Health of the Russian Federation
Moscow
Russian Federation
117997

Study participating centre
Federal State Budgetary Institution “Moscow Helmholtz Research Institute of Eye Diseases" of the Ministry of Healthcare of the Russian Federation
14/19, Sadovaya-Chernogryazskaya str.
Moscow
Russian Federation
105062

Study participating centre
Federal State Budgetary Educational Institution of Higher Education “Saint Petersburg State Pediatric Medical University” of the Ministry of Healthcare of the Russian Federation
2 Litovskaya str.
Saint Petersburg
Russian Federation
194100

Study participating centre
Federal State Budgetary Educational Institution of Higher Education "Pavlov First Saint Petersburg State Medical University" of the Ministry of Healthcare of the Russian Federation
6/8 L’va Tolstogo str.
Saint Petersburg
Russian Federation
197022

Study participating centre
Regional Budgetary Healthcare Institution “Ivanovo Regional Clinical Hospital”
1 Luybimova str.
Ivanovo
Russian Federation
153040

Sponsor information

Organisation

URSAPHARM Arzneimittel GmbH

Sponsor details
Industriestrasse 35
Saarbrücken
Germany
66129
+49 (0)6805 9292 132
dorothea.gross@ursapharm.de

Sponsor type
Industry

Website
https://www.ursapharm.de/

Funder(s)

Funder type
Industry

Funder Name
URSAPHARM Arzneimittel GmbH

Results and Publications

Publication and dissemination plan
1. Additional documents not available in web format, please use the contact details to request study-related material
2. Planned publication in a high-impact peer-reviewed journal

Intention to publish date
04/08/2021

Individual participant data (IPD) sharing plan
The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication

IPD sharing plan summary
Other

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		17/05/2022	09/09/2022	Yes	No